News

CPP-109 is Catalyst’s tablet formulation of vigabatrin being developed as a treatment for cocaine and methamphetamine addiction, as well as other addictions and obsessive-compulsive disorders. The randomized, double-blind,

Dr Caudrelier joined Theratechnologies in August 2007 and worked actively in the completion of the Phase III clinical program evaluating tesamorelin in HIV-associated lipodystrophy. Dr Caudrelier’s responsibilities will

Abbott’s 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing

The single-dose, open-label study is designed to assess the pharmacokinetics, safety and tolerability of a gluteal injection of this risperidone formulation in approximately 26 patients diagnosed with chronic,

Mr Boisjoli most recently served as CFO and co-founder of Xanthus Pharmaceuticals, a Boston-based biotechnology company, where he was responsible for all financial business and operations and was

The FDA had requested that the data in a single study be reformatted. In addition, GSK conducted a review of other clinical studies taking this input into account.

Zingo powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age.

The Phase I clinical trial is a randomized, single-blind, placebo-controlled, single-ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered ARRY-300 in healthy volunteers. Kevin

Before joining ImmunoGen, Mr Perry was CFO of Elixir Pharmaceuticals, where he was extensively involved in partnering and fundraising activities. Prior to Elixir, he was CFO of Domantis,